Status:
COMPLETED
Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
Lead Sponsor:
San Francisco Department of Public Health
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Public Health Foundation Enterprises, Inc.
Conditions:
Substance Abuse
HIV Infections
Eligibility:
MALE
18-60 years
Phase:
PHASE2
Brief Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No st...
Detailed Description
The high rate of meth use among MSM is paralleled by evidence of rises in sexual risk behavior and HIV infection among this population. The MSM meth epidemic, and its link with HIV transmission, under...
Eligibility Criteria
Inclusion
- HIV-negative by rapid test or able to document HIV infection through healthcare provider's note or documentation of laboratory test;
- Reports anal sex with men in prior 3 months while using meth
- Diagnosed with meth dependence as determined by SCID
- Interested in stopping or reducing meth use
- Meth-positive urine on screening
- No known allergies to bupropion
- No current acute illnesses
- Able and willing to provide informed consent and to be followed over a 3-month period
- Baseline CBC and electrolytes within institutional limits.
Exclusion
- History of seizure
- High risk for seizure, including: recent (last 24 months) head trauma, brain injury or surgery; using theophylline or systemic steroids; prior or current history of anorexia or bulimia; prior or current history of alcohol withdrawal symptoms
- Measured moderate or severe liver disease (LFTs \> 3 times normal) or history of chronic liver disease
- Impaired renal function (creatinine clearance \< 90 ml/min)
- Evidence of current major depression, as determined by SCID
- Taking anti-depressant medication within last 30 days
- Currently on any bupropion-containing regimen
- Currently using or unwilling not to use pseudoephedrine-containing products (causes false + urines for meth use) for trial duration
- Currently taking antiretroviral therapy (ART)
- CD4 count \< 200 cells/mm3
- Any condition that, in the principal investigator's judgment, interferes with safe study participation.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00318409
Start Date
September 1 2006
End Date
November 1 2007
Last Update
October 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco Department of Public Health, HIV/AIDS Office
San Francisco, California, United States, 94102